PT
Insider
Paul Peter Tak
Chief Executive OfficerPaul Peter Tak (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Candel Therapeutics, Inc. (CADL). The largest single filing was $3.2M of CADL (280,245 sh across 2 lots, as filed), executed Sep 10.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.2M
shares × price, as filed
Last traded
Sep 11
Filed Sep 11
Median ADV $19.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $3.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
CADLRecent filings
CADLSALE
Candel Therapeutics, Inc.
View filing →
$3.2M280,245 sh across 2 lots
Exec Sep 10
Filed Sep 11 · 6:12 PM ET CADLSALE Candel Therapeutics, Inc. View filing → $226K
25,772 sh × $8.77
Exec Mar 18 2025
Filed Mar 20 2025 · 5:30 PM ET CADLSALE Candel Therapeutics, Inc. View filing → $157K
21,704 sh × $7.23
Exec Jan 15 2025
Filed Jan 17 2025 · 5:30 PM ET CADLSALE Candel Therapeutics, Inc. View filing → $174K
21,172 sh × $8.22
Exec Jan 8 2025
Filed Jan 10 2025 · 5:30 PM ET CADLSALE Candel Therapeutics, Inc. View filing → $223K
48,847 sh × $4.56
Exec Nov 29 2024
Filed Dec 3 2024 · 5:30 PM ET